Literature DB >> 14349955

The transmission of infectious mononucleosis.

R J HOAGLAND.   

Abstract

Entities:  

Keywords:  INFECTIOUS MONONUCLEOSIS/transmission; SALIVA

Mesh:

Year:  1955        PMID: 14349955     DOI: 10.1097/00000441-195503000-00003

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


× No keyword cloud information.
  44 in total

1.  PYREXIA AFTER HEART SURGERY DUE TO VIRUS INFECTION TRANSMITTED BY BLOOD TRANSFUSION.

Authors:  B A ROSS
Journal:  Thorax       Date:  1964-03       Impact factor: 9.139

2.  THE INCUBATION PERIOD OF INFECTIOUS MONONUCLEOSIS.

Authors:  R J HOAGLAND
Journal:  Am J Public Health Nations Health       Date:  1964-10

3.  Toxoplasmosis.

Authors:  G E FFRENCH
Journal:  Can Med Assoc J       Date:  1959-06-01       Impact factor: 8.262

4.  Infectious reticulo-endotheliosis.

Authors:  L F KOYL
Journal:  Can Med Assoc J       Date:  1956-11-01       Impact factor: 8.262

5.  Infectious mononucleosis.

Authors:  J LOWNEY; G X TRIMBLE
Journal:  Can Med Assoc J       Date:  1956-04-15       Impact factor: 8.262

Review 6.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 7.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

8.  A model of host response to a multi-stage pathogen.

Authors:  Edgar Delgado-Eckert; Michael Shapiro
Journal:  J Math Biol       Date:  2010-10-02       Impact factor: 2.259

9.  Infectious mononucleosis and mononucleosis syndromes.

Authors:  M Fiala; D C Heiner; J A Turner; B Rosenbloom; L B Guze
Journal:  West J Med       Date:  1977-06

10.  The formation of immunoglobulins by human tissues in vitro. IV. Circulating lymphocytes in normal and pathological conditions.

Authors:  R van Furth; H R Schuit; W Hijmans
Journal:  Immunology       Date:  1966-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.